Autolus Therapeutics plc logo
Autolus Therapeutics plc AUTL
$ 1.51 0.0%

Quarterly report 2025-Q3
added 03-07-2026

report update icon

Autolus Therapeutics plc Income Statement 2011-2026 | AUTL

Annual Income Statement Autolus Therapeutics plc

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

424 M 1.09 B 299 M 270 M 332 M 352 M 1.08 B 43.4 M - - - - - -

Shares

255 M 174 M 95 M 72.1 M 51.6 M 43.1 M 39.4 M 13.8 M - - - - - -

Historical Prices

1.66 6.25 3.15 3.74 6.44 8.18 27.4 - - - - - - -

Net Income

-221 M -208 M -149 M -142 M -142 M -124 M -20.6 M -19.7 M -12.6 M - - - - -

Revenue

- - - - 242 K 2.91 M 1.41 M 1.69 M 1.21 M - - - - -

Operating Income

-241 M -180 M -143 M -141 M -168 M -146 M -25 M -23.4 M - - - - - -

Interest Expense

9.29 M 45.1 M 8.9 M 1.1 M 1.35 M 4.51 M 1.1 M -46 K -26 K - - - - -

EBITDA

-234 M -173 M -136 M -133 M -162 M -141 M -23.3 M -22.4 M -13.9 M - - - - -

Operating Expenses

- - - - - 145 M 58.9 M 25.1 M 15.6 M - - - - -

General and Administrative Expenses

- 46.7 M 31.9 M 31.9 M 35 M 39.5 M 22.8 M 9.1 M 5.15 M - - - - -

All numbers in USD currency

Quarterly Income Statement Autolus Therapeutics plc

2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

266 M 266 M 266 M 266 M 266 M 222 M 174 M 174 M 174 M - 91.2 M - - - - - 62.4 M - 52.1 M 52 M 49.9 M - 44.5 M 43.6 M 39.5 M 39.4 M 39.2 M 29.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-79.1 M -47.9 M -70.2 M -82.1 M -58.3 M -52.7 M -45.8 M -45.6 M -39.8 M - -42.8 M - - - - - -33.3 M - -37.3 M -32 M -29.9 M - -27.2 M -28.5 M -27.2 M -20.6 M -12.9 M -7.65 M -16.7 M -7.52 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

21.2 M 20.9 M 8.98 M - - 10.1 M - - - - - - - - - - 269 K - - 293 K 338 K - 297 K 338 K 1.96 M 296 K 307 K 443 K - 231 K - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

28.6 M 24.4 M 18 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-71.6 M -61.2 M -65.2 M -67.9 M -58.9 M -38.8 M -42.9 M -44.4 M -39.1 M - -43.5 M - - - - - -39.9 M - -42.7 M -39.5 M -38.6 M - -35.6 M -37.2 M -30.2 M -25 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

10.5 M -6.83 M 10.1 M 10.7 M 10.2 M 19.3 M 5.01 M 5.02 M 4.9 M - 1.85 M - - - - - 838 K - -2.51 M 525 K 4.48 M - 3.26 M 4.38 M -984 K 1.1 M - - - -685 K - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-69.5 M -59.1 M -63.2 M -66 M -57 M -37 M -41.5 M -42.9 M -37.2 M - -41.7 M - - - - - -38.2 M - -41.2 M -38.3 M -37.3 M - -34.5 M -36.1 M -28.5 M -24.4 M 300 K 500 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - 35.6 M 37.2 M - 25 M 17.1 M 16.5 M - 8.42 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

36.3 M 30.3 M 29.5 M 27.3 M 21.9 M 18.2 M 10.6 M 11.1 M 9.28 M - 8.23 M - - - - - 8.74 M - 9.84 M 8.51 M 7.61 M - 8.6 M 11.4 M 9.56 M 7.59 M 7.27 M 8.1 M - 3.08 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Autolus Therapeutics plc (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.55 -0.28 % $ 1.06 B canadaCanada
Adagene Adagene
ADAG
$ 3.91 -2.01 % $ 220 M chinaChina
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
AC Immune SA AC Immune SA
ACIU
$ 3.32 6.07 % $ 229 M schweizSchweiz
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 4.11 -2.61 % $ 105 M schweizSchweiz
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.79 0.04 % $ 4.31 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
argenx SE argenx SE
ARGX
$ 706.03 0.39 % $ 25 B niderlandNiderland
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.34 -7.48 % $ 8.04 B australiaAustralia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 228.06 -1.28 % $ 5 B danmarkDanmark
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.43 -4.19 % $ 7.46 B israelIsrael
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.51 1.04 % $ 213 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 6.39 -3.62 % $ 175 M israelIsrael
BioNTech SE BioNTech SE
BNTX
$ 94.86 4.77 % $ 27.2 B germanyGermany
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 8.28 2.86 % $ 1.34 B britainBritain
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
$ 1.14 2.7 % $ 34.3 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 6.13 1.32 % $ 500 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Equillium Equillium
EQ
$ 2.15 -7.33 % $ 74.7 M usaUSA